Changes in ATT were significantly associated with the occurrence of MACE, with higher hazard ratios for patients with ATT at follow-up compared to those without ATT.
Subjects with better lipid trafficking scores had lower circulating levels of pro-atherogenic lipoproteins and lower odds of myocardial infarction and stroke. Poor lipid trafficking scores were associated with not reaching LDL-C target levels on statin therapy.
PCSK9 inhibitors resulted in an average reduction of Lp(a) levels by 27%. Additionally, there were concurrent reductions in LDL-C, non-HDL-C, total cholesterol, triglycerides, ApoB, and ApoA-1, along with an increase in HDL-C levels.
PCSK9I was associated with a lower risk of new-onset major adverse cardiovascular events (MACE) compared to ezetimibe, with a hazard ratio of 0.59. Evolocumab showed significantly lower risks of myocardial infarction, heart failure, and stroke/transient ischemic attack compared to ezetimibe.
Significant reductions in triglyceride levels and improvements in cholesterol profiles were observed, with the percentage of patients achieving triglyceride levels <1.7 mmol/L increasing from 13.1% to 54%.
Statin therapy was found to significantly reduce total atheroma volume (TAV) and plaque volume (PV), indicating a beneficial effect on plaque regression and stabilization in patients with coronary heart disease.
Significant increase in HDL cholesterol content without affecting the metabolism of apolipoproteins A1, A2, or B100, suggesting potential benefits for cholesterol balance and atherogenesis.
The study found that more aggressive lipid-lowering therapy (ezetimibe and PCSK9i) was more often prescribed to White individuals, those with higher income, and individuals with advanced education, indicating a disparity in treatment access and equity.
Women experienced significant reductions in LDL-C, non-HDL-C, total cholesterol, and apolipoprotein B compared to men, indicating a greater efficacy of bempedoic acid in women with hypercholesterolemia.
Identifying individuals with the p.G137S variant allows for early intervention, which can significantly improve health outcomes and reduce the risk of cardiovascular diseases in the Greenlandic population.
Berberine significantly reduced LDL cholesterol by 0.45 mmol/L, total cholesterol by 0.47 mmol/L, triglycerides by 0.32 mmol/L, and apolipoprotein B by 0.25 mg/dL. It also increased HDL cholesterol by 0.06 mmol/L, with a notable sex-specific effect where women experienced an increase while men had a decrease.
High-risk women on GDSI had a lower risk of mortality compared to men on similar treatment, indicating that GDSI significantly improved survival in both sexes regardless of ASCVD risk group.
Statin therapy was linked to a decreased risk of myocardial infarction, major cerebrovascular events, major coronary events, composite cardiovascular outcomes, revascularizations, angina, and hospitalization for cardiovascular causes. All-cause mortality benefits were observed in populations with diabetes and increased cardiovascular risk.
Women with the *5 genotype had a higher prevalence of clinically high total cholesterol despite statin treatment, indicating a need for genotype-guided statin selection to improve treatment effectiveness.
Positive outcomes of lipoprotein apheresis in children with HoFH include significant reductions in LDL-C levels, which can help prevent the early onset of atherosclerotic cardiovascular disease and improve overall cardiovascular health.
After 4 weeks of treatment, total cholesterol levels decreased by 26%, LDL by 33%, and triglycerides by 19%, while HDL increased by 18%. Improvements in endothelial dysfunction and lipid peroxidation were also observed. After 12 months, regression of atherosclerotic plaques was noted.
The addition of ezetimibe to statin therapy resulted in a significant reduction in LDL-C levels compared to statin monotherapy. It also led to a notable decrease in fibro-fatty plaque volume, indicating potential benefits in reducing coronary atherosclerosis.
Fluvastatin treatment is associated with a moderate beneficial effect on SARS-CoV-2 infection, suggesting it poses no additional risk to individuals exposed to the virus and may improve clinical outcomes.
Patients with the NAT2 *1 allele showed better responses to simvastatin, with significant reductions in LDL cholesterol levels compared to those with the *5 allele.
CETP inhibition was associated with lower LDL-C, lower systolic blood pressure, and a protective effect against coronary heart disease, angina, intracerebral hemorrhage, and heart failure in both European and East Asian populations.
Low- or high-energy and low-quality breakfasts were associated with higher adiposity, increased triglycerides, and lower HDL cholesterol levels. Low-quality breakfasts were also linked to poorer kidney function.
EA may improve recovery from ischemic stroke by modulating cholesterol levels, reducing inflammation, and enhancing vascular repair processes.
Positive outcomes of implementing these guidelines include improved accuracy in variant classification, enhanced patient care through targeted therapies, and better family screening practices, ultimately leading to reduced cardiovascular risks in FH patients.
The intervention led to a significant decrease in the suite of PFAS of concern in the cholesterol intervention group, suggesting a reduction in PFAS body burden.
The pooled Incremental Net Benefit (INB) from the analysis indicated that Ezetimibe plus statin therapy is significantly cost-effective compared to other lipid-lowering agents or placebo, with a pooled INB of $4,274. Subgroup analyses showed even higher cost-effectiveness in high-income countries and for primary prevention.
Improved patient adherence to omega-3 therapy through the use of digital technology tools, leading to better management of triglyceride levels and reduced cardiovascular risk.
The supplementation with VE and mixed berry juice significantly reduced LDL-C levels and increased the abundance of beneficial gut bacteria.
The study reveals significant genetic correlations between AAA and 21 cardiometabolic traits, suggesting shared causal mechanisms. It identifies several drug candidates with high potential for treating AAA in patients with comorbidities, providing insights into the genetic underpinnings of these conditions.
Identification of 225 lipid risk variants associated with 168 distinct lipoprotein and metabolic traits, enhancing understanding of lipid metabolism and potential therapeutic targets for dyslipidemia and ASCVD.
Bempedoic acid significantly lowered LDL-C, total cholesterol, non-HDL cholesterol, apolipoprotein B, and hsCRP in both MetS and non-MetS patients, with greater LDL-C reductions observed in patients with MetS. Additionally, it improved glycated hemoglobin and fasting plasma glucose levels specifically in patients with MetS.
Higher adherence to the Mediterranean diet was associated with lower cardiometabolic risk scores at both 16 and 34 weeks of gestation, indicating better maternal and fetal health outcomes.
Patients tested for Lp(a) were more frequently initiated on lipid lowering therapies, with those having elevated Lp(a) levels more likely to start non-statin therapies such as ezetimibe and PCSK9 inhibitors.
Egg consumption was associated with beneficial metabolic markers, potentially offering a protective effect against cardiovascular diseases.
Patients in the intervention group experienced a significant reduction in LDL-C levels (mean change of -13.1 mg/dL) compared to the control group (mean change of 6.6 mg/dL), indicating that genetic risk disclosure can effectively lower cholesterol levels in patients with FH.
Genetic mimics of statins were associated with a lower risk of gallstone disease, with an odds ratio of 0.72, indicating a protective effect against gallstone formation.
The study found that high inflammatory risk (measured by hs-CRP) was a stronger predictor of MACCEs than cholesterol risk (measured by LDL-C) in PCI-treated patients. Specifically, high inflammatory risk was independently predictive of cardiovascular outcomes in patients with diabetes mellitus and those on underpowered statin therapy.
Lower baseline LDL-C levels were associated with a significantly higher risk of all-cause death, cardiovascular death, non-cardiovascular death, sudden death, and heart failure admission in patients undergoing coronary revascularization.